Arthur Kuan

Chief Executive Officer

Arthur serves as Chief Executive Officer at CG Oncology. Having lost his father to cancer this is personal for him. Arthur was recognized in 2022 by Business Insider’s 30 People Under 40 Who Are Transforming Healthcare. In 2020, he was named a Forbes 30 Under 30 featured honoree in healthcare. At Moffitt Cancer Center, Arthur serves on the IP Commercialization Strategy Committee. Arthur is a Founding Member of Ally Bridge Group, a global healthcare-focused investment platform, and played an active role in managing the fund’s portfolio companies. Previously, Arthur was a member of Themes Investment Partners, a Private Equity fund where he focused on healthcare and biotech investment opportunities. He began his career at Dinova Capital, a MedTech incubator fund, focusing on cross-border technology transfer and new company formation. Arthur received his M.S. in Biotechnology from the Johns Hopkins University and his B.A. in Biology from the University of Pennsylvania.

James Burke, MD

Chief Medical Officer

Georg Roth, PhD

Chief Technical Officer

Georg serves as Chief Technology Officer and is responsible for technical operations at CG Oncology. He has over 30 years of experience in the biopharmaceutical industry, developing biological processes and directing manufacturing operations. Until 2019, Georg was COO and SVP Technical Operations at Sillajen Biotherapeutics where he oversaw U.S. operations and headed all technical functions for the development of oncolytic viruses. Prior to Sillajen Biotherapeutics, Georg was VP Technical Operations at Jennerex. Earlier in his career, he held roles of increasing responsibility at Dynavax Technologies, Berlex Biosciences and Schering AG. Georg earned a diploma and PhD in Chemical Engineering from the Technical University Berlin, Germany.

Bing Kung

VP, Business Development

Bing serves as VP, Business Development at CG Oncology, where he has successfully led multiple clinical trial collaborations with Big Pharma, as well as cross-border licensing and strategic investment transactions with partners in Asia. The breadth of transactions accomplished reflects Bing’s unique combination of experience as a business development executive, investment banker and scientist. Bing is passionate about moving science into meaningful commercial vehicles and has executed over 80 partnership, M&A and financing deals in the life sciences sector, including those for immuno-oncology and platform technology companies. Prior to CG Oncology, Bing managed business development activities at Ascendancy Healthcare, which provided Western-based companies partnership solutions in China and other Asian markets. Previously, he was an investment banker at Torreya Partners, MTS Health Partners and Aquilo Partners. Bing began his career as a research scientist in the Divisions of Oncology and Neurology at The Children’s Hospital of Philadelphia, where he authored peer-reviewed publications on the molecular basis of the pediatric solid tumor neuroblastoma. He received his Master’s in Biotechnology and his Bachelor’s in Biology from the University of Pennsylvania.

Amy Steele

VP, Finance, Accounting & Administration

Amy serves as the VP of Finance, Accounting and Administration at CG Oncology and supported several successful debt and equity financings. Amy brings many years of experience in finance, accounting, internal audit as well as pre- to global commercial pharmaceutical operations. She is responsible for overseeing company-wide functions related to financial planning and analysis, accounting and financial reporting, investor/shareholder reporting, treasury, taxation, information technology, business operations and external audits. Amy began her career in various financial, accounting and auditing roles with increasing responsibilities at Deutsche Bank, TWi Pharmaceuticals, Inc. and Genovi Pharmaceuticals, Inc. She possesses outstanding problem-solving abilities and is recognized for establishing cross functional collaboration as a business partner, initiating and managing change, developing high performing teams, as well as planning and executing corporate strategies and company-wide initiatives. Amy received her B.A. degree in Business Economics / Accounting from University of California Los Angeles.

Arthur Kuan

Chief Executive Officer

Arthur currently serves as Chief Executive Officer and Director on the Board at CG Oncology, a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies, including an oncolytic virus for the treatment of bladder cancer and a variety of other solid tumor types. Arthur is a Founding Member of Ally Bridge Group, a global healthcare-focused investment platform, and plays an active role in managing the fund’s portfolio companies. Previously, Arthur was a member of Themes Investment Partners, a Private Equity fund based in Hong Kong, where he played a central role in coordinating cross-border technology transfer and regulatory submissions for portfolio companies. He began his career in an operational role at Dinova Capital, a Shanghai-based, medical technology incubator fund, evaluating medical device investment opportunities. Arthur received his M.S. in Biotechnology from the Johns Hopkins University and his B.A. in Biology from the University of Pennsylvania.

Ronald Cheng

Managing Director, Wellchamp Capital

Ronald has more than 20 years of experience in the Finance and Investment realm with an emphasis in media and biotechnology. He is the Founder and Managing Director at Wellchamp Capital Limited, a Hong Kong SFC registered asset management and investment advisory firm. In 2002, Ronald was Investor and Director of Plasmagene Bioscience, a biotechnology company founded by Dr. Alex Yeung, which eventually became listed as a part of the Hong Kong Stock Exchange (SEHK). Ronald was also Investor and Director of New Media Corp, a telecommunications media company invested in news and publication since 1975. Ronald holds a B.S. from The Chinese University of Hong Kong in Business Administration.

Brian Liu

Principal, Longitude Capital

Brian Liu, MD, is a Principal at Longitude Capital. Dr. Liu is a board observer at Quanta Therapeutics and Rivus Pharmaceuticals. He previously served as a board observer at Endeavor Biomedicines, Inflazome (acquired by Roche), Talaris Therapeutics (TALS), and Vera Therapeutics (VERA). Prior to joining Longitude Capital in 2018, Dr. Liu was an Engagement Manager in the pharmaceuticals practice of McKinsey & Company. Dr. Liu holds an MD from Stanford School of Medicine and a BS in Biomedical Engineering from The Johns Hopkins University.

Jim Mulé, PhD

Director of Cell-based Therapies, Moffitt Cancer Center

Jim is Associate Center Director, the U.S. Senator Connie Mack (ret.) & Family Endowed Chair for Melanoma Research and Treatment, and Director of Cell-based Therapies at the Moffitt Cancer Center, Tampa, Florida. He is recognized for his research and clinical trial contributions to cancer immunotherapy, particularly in melanoma. His translational work in this area has helped to develop new treatments for advanced cancer patients. He has published nearly 200 articles. Jim serves on Advisory Boards of numerous biotechnology and pharma companies as well as investment funds (e.g., OncoPep, Fulgent Diagnostics, UbiVac, Lion Biotech, Orpheus Therapeutics, Vault Pharma, Celgene, Select BioVenture Partners, Noble Life Science Partners, among others). Jim remains a long-standing special government employee to the FDA (CDER and CBER) and the NCI. He was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee of CBER, FDA. He currently serves on the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director’s Board of Scientific Counselors (BSC-A). Jim also serves on the Editorial Boards of several peer-reviewed journals, including Scientific Reports (nature.com), Journal of Immunotherapy, and Cancer Immunology Research (AACR). Jim received his professional degrees from the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington. He then received his formal postgraduate training at the Surgery Branch, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland, where he became a Senior Investigator with tenure. Jim moved to Palo Alto, CA, where he helped to launch and scientifically direct two biotechnology companies and was also an adjunct professor at Stanford University. He then moved to Ann Arbor, Michigan to become the Director of the Tumor Immunology and Immunotherapy Program at the University of Michigan Comprehensive Cancer Center, the Maude T. Lane Endowed Professor of Surgery with tenure, Department of Surgery, and Professor in the Department of Internal Medicine.

Osamu Nakanishi, PhD

Kissei Pharmaceutical

Osamu has over ten years of pharmaceutical R&D experience at Kissei Pharmaceutical. He currently belongs to BD & Licensing. He started to be involved in CG0070 when he was a researcher at Pharmacology and Pharmacokinetics Research Lab. After transfer to Strategic Alliance / Corporate Development, he played an integral part in the scientific due diligence for the CG0070 program. He has experience in drug discovery for urology, nephrology, autoimmune diseases, and pain. He received a Ph.D. in Biochemistry from University of Tokyo, Graduate school of Science.

Leonard Post, PhD

Chief Scientific Officer, Vivace Therapeutics

Len has over three decades of pharmaceutical R&D experience. He is currently Chief Scientific Officer at Vivace Therapeutics. Previous experience included roles as Chief Scientific Officer of BioMarin, Chief Scientific Officer of LEAD Therapeutics, SVP of R&D at Onyx Pharmaceuticals, and positions at Parke-Davis and Upjohn. His experience with oncolytic viruses began with the adenovirus program at Onyx, and later as a member of the Boards of Directors of BioVex and then Viralytics. He is currently a member of the boards of directors at Vivace, Orphagen, Fedora, and Oxyrane. Len has a Ph.D. in Biochemistry and did postdoctoral work in virology, including some of the early work on genetic engineering of herpes simplex virus.

Jue Pu

Lepu Medical

Jue leads the cancer biomarker and liquid biopsy research and development at Lepu Medical. She also leads international investment for Lepu Medical, with successful investments including Viralytics (acquired by Merck). Jue holds a Master of Science degree in Materials Science Engineering at Stanford University. She holds a dual undergraduate degree, summa cum laude, from the Wharton School of Finance and Materials Science Engineering at the University of Pennsylvania.

Simone Song

Senior Partner, ORI Capital

Simone is Founder and Senior Partner of ORI Capital. She was the former Head of Goldman Sachs Healthcare Investment Banking for Greater China. Simone has more than 25 years of experience in healthcare sector. Prior to joining Goldman Sachs, she was a Managing Director of Cowen Group, a member of the advisory board of AXA Investment Managers, and an executive board advisor to AXA Asia Pacific Holdings. Simone holds a B.A. in Economics from Fudan University in China and an M.A. in Economics from Claremont Graduate School in the United States.